These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 7981584)

  • 21. Tryptophan contaminants associated with eosinophilia-myalgia syndrome. The Eosinophilia-Myalgia Studies of Oregon, New York and New Mexico.
    Philen RM; Hill RH; Flanders WD; Caudill SP; Needham L; Sewell L; Sampson EJ; Falk H; Kilbourne EM
    Am J Epidemiol; 1993 Aug; 138(3):154-9. PubMed ID: 8356958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review of L-tryptophan and eosinophilia-myalgia syndrome.
    Roufs JB
    J Am Diet Assoc; 1992 Jul; 92(7):844-50. PubMed ID: 1624654
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eosinophilia myalgia syndrome.
    Blackburn WD
    Semin Arthritis Rheum; 1997 Jun; 26(6):788-93. PubMed ID: 9213377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune-mediated mechanisms and immune activation of fibroblasts in the pathogenesis of eosinophilia-myalgia syndrome induced by L-tryptophan.
    Illa I; Dinsmore S; Dalakas MC
    Hum Pathol; 1993 Jul; 24(7):702-9. PubMed ID: 8100551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 3-(Phenylamino)alanine, a novel aniline-derived amino acid associated with the eosinophilia-myalgia syndrome: a link to the toxic oil syndrome?
    Mayeno AN; Belongia EA; Lin F; Lundy SK; Gleich GJ
    Mayo Clin Proc; 1992 Dec; 67(12):1134-9. PubMed ID: 1469924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A murine model of the eosinophilia-myalgia syndrome induced by 1,1'-ethylidenebis (L-tryptophan).
    Silver RM; Ludwicka A; Hampton M; Ohba T; Bingel SA; Smith T; Harley RA; Maize J; Heyes MP
    J Clin Invest; 1994 Apr; 93(4):1473-80. PubMed ID: 8163652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bias or biology: evaluating the epidemiologic studies of L-tryptophan and the eosinophilia-myalgia syndrome.
    Horwitz RI; Daniels SR
    J Rheumatol Suppl; 1996 Oct; 46():60-72. PubMed ID: 8895182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Persistent microvasculopathy in chronic eosinophilia-myalgia syndrome.
    Smith SA
    Adv Exp Med Biol; 1996; 398():359-64. PubMed ID: 8906289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eosinophilia-myalgia syndrome in Germany: an epidemiologic review.
    Carr L; Rüther E; Berg PA; Lehnert H
    Mayo Clin Proc; 1994 Jul; 69(7):620-5. PubMed ID: 8015323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eosinophilia myalgia syndrome: absence of immunoglobulin reactivity suggests a cellular rather than humoral mechanism.
    Villanova M; De Clerck LS; Cras P; Guazzi GC; Martin JJ
    Acta Neurol Belg; 1994; 94(3):200-4. PubMed ID: 7976226
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gastrointestinal involvement in L-tryptophan (L-Trp) associated eosinophilia-myalgia syndrome (EMS).
    De Schryver-Kecskemeti K; Bennert KW; Cooper GS; Yang P
    Dig Dis Sci; 1992 May; 37(5):697-701. PubMed ID: 1563309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Upper extremity contractures in a patient with eosinophilia-myalgia syndrome.
    Marchman HB; Gleason CB; Shaw JC
    Arch Phys Med Rehabil; 1991 Nov; 72(12):1029-30. PubMed ID: 1953317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidemiology of potential association between L-tryptophan ingestion and eosinophilia-myalgia syndrome.
    Daniels SR; Hudson JI; Horwitz RI
    J Clin Epidemiol; 1995 Dec; 48(12):1413-27; discussion 1429-40. PubMed ID: 8543957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. L-tryptophan and the eosinophilia-myalgia syndrome: a clinical and laboratory study.
    McKeon P; Swanwick G; Manley P
    Acta Psychiatr Scand; 1994 Dec; 90(6):451-4. PubMed ID: 7892779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Two cases of L-tryptophan ingestion induced eosinophilia-myalgia syndrome].
    Mizutani T; Mizutani H; Hashimoto K; Kishida M; Taniguchi H; Okada H; Murata M; Nakamura Y; Shimizu M
    Nihon Hifuka Gakkai Zasshi; 1991 Apr; 101(5):561-6. PubMed ID: 1890752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calcinosis cutis in a patient with eosinophilia-myalgia syndrome: case report.
    Smith E; Gordon M; Lebwohl M
    Cutis; 2006 Jun; 77(6):361-4. PubMed ID: 16838769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alterations in tryptophan metabolism in the toxic oil syndrome and in the eosinophilia-myalgia syndrome.
    Silver RM; Sutherland SE; Carreira P; Heyes MP
    J Rheumatol; 1992 Jan; 19(1):69-73. PubMed ID: 1532618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. L-tryptophan syndrome: histologic features of scleroderma-like skin changes.
    Guerin SB; Schmidt JJ; Kulik JE; Golitz LE
    J Cutan Pathol; 1992 Jun; 19(3):207-11. PubMed ID: 1401345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic fatigue: a peculiar evolution of eosinophilia myalgia syndrome following treatment with L-tryptophan in four Italian adolescents.
    Priori R; Conti F; Luan FL; Arpino C; Valesini G
    Eur J Pediatr; 1994 May; 153(5):344-6. PubMed ID: 8033924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid HPLC screening method for contaminants found in implicated L-tryptophan associated with eosinophilia myalgia syndrome and adulterated rapeseed oil associated with toxic oil syndrome.
    Williamson BL; Tomlinson AJ; Hurth KM; Posada de la Paz M; Gleich GJ; Naylor S
    Biomed Chromatogr; 1998; 12(5):255-61. PubMed ID: 9787895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.